BRPI1013771A2 - "células-tronco mesenquimais projetadas e método de uso das mesmas para tratar tumores." - Google Patents

"células-tronco mesenquimais projetadas e método de uso das mesmas para tratar tumores."

Info

Publication number
BRPI1013771A2
BRPI1013771A2 BRPI1013771A BRPI1013771A BRPI1013771A2 BR PI1013771 A2 BRPI1013771 A2 BR PI1013771A2 BR PI1013771 A BRPI1013771 A BR PI1013771A BR PI1013771 A BRPI1013771 A BR PI1013771A BR PI1013771 A2 BRPI1013771 A2 BR PI1013771A2
Authority
BR
Brazil
Prior art keywords
designed
stem cells
mesenchymal stem
treat tumors
tumors
Prior art date
Application number
BRPI1013771A
Other languages
English (en)
Portuguese (pt)
Inventor
Peter Nelson
Original Assignee
Apceth Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apceth Gmbh & Co Kg filed Critical Apceth Gmbh & Co Kg
Publication of BRPI1013771A2 publication Critical patent/BRPI1013771A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI1013771A 2009-04-13 2010-04-13 "células-tronco mesenquimais projetadas e método de uso das mesmas para tratar tumores." BRPI1013771A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16878709P 2009-04-13 2009-04-13
PCT/EP2010/054844 WO2010119039A1 (en) 2009-04-13 2010-04-13 Engineered mesenchymal stem cells and method of using same to treat tumors

Publications (1)

Publication Number Publication Date
BRPI1013771A2 true BRPI1013771A2 (pt) 2016-04-05

Family

ID=42270435

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013771A BRPI1013771A2 (pt) 2009-04-13 2010-04-13 "células-tronco mesenquimais projetadas e método de uso das mesmas para tratar tumores."

Country Status (12)

Country Link
US (2) US9434925B2 (cg-RX-API-DMAC7.html)
EP (1) EP2419113B1 (cg-RX-API-DMAC7.html)
JP (1) JP5727458B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120088542A (cg-RX-API-DMAC7.html)
CN (1) CN102695517B (cg-RX-API-DMAC7.html)
AU (1) AU2010237130B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1013771A2 (cg-RX-API-DMAC7.html)
CA (1) CA2758120C (cg-RX-API-DMAC7.html)
IL (1) IL215581A0 (cg-RX-API-DMAC7.html)
RU (1) RU2539099C2 (cg-RX-API-DMAC7.html)
SG (1) SG175127A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010119039A1 (cg-RX-API-DMAC7.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100183558A1 (en) 2008-10-17 2010-07-22 Zhennan Lai Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
US20130171115A1 (en) * 2011-12-30 2013-07-04 Gang Li Cell-mediated gene therapy for cancer using mesenchymal stem cells expressing a suicide gene
CN105950630A (zh) * 2012-02-01 2016-09-21 浦项工科大学校产学协力团 同时表达十二聚体trail及hsv-tk自杀基因的载体及利用其的抗癌干细胞治疗剂
US20130203166A1 (en) * 2012-02-06 2013-08-08 Protobios Llc Stimulation of multipotency of mesenchymal stem cells by chemokine ccl5
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
US20140065110A1 (en) 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods
ES2748662T3 (es) * 2012-11-05 2020-03-17 Institute For Res In Biomedicine Irb Roedores inmunodeficientes modificados genéticamente y métodos de uso de los mismos
US10472647B2 (en) 2012-12-21 2019-11-12 The Administrators Of The Tulane Educational Fund Primary mesenchymal stem cells as a vaccine platform
WO2015100268A1 (en) * 2013-12-23 2015-07-02 The Regents Of The University Of California Mesenchymal stem cells for targeted cancer therapy
CA2936483A1 (en) * 2014-01-17 2015-07-23 Wake Forest University Health Sciences Methods for enhancing the delivery of active agents
CA2956987C (en) * 2014-08-18 2023-03-21 Apceth Gmbh & Co. Kg Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
CA3003133C (en) * 2014-10-24 2020-09-15 StemImmune, Incorporated Combination immunotherapy approach for treatment of cancer
CN104622903B (zh) * 2015-01-20 2018-10-09 奥思达干细胞有限公司 抗恶性黑色素瘤的干细胞制剂及其制备方法
EP3247808B1 (en) 2015-01-21 2021-05-05 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
WO2016138340A1 (en) * 2015-02-27 2016-09-01 Saint Louis University Tumor suppressor sall1 as a therapeutic agent for treating cancer
EP3262159B1 (en) * 2015-02-27 2019-07-24 Apceth GmbH & Co. KG Genetically modified mesenchymal stem cell expressing klotho
WO2016146819A1 (en) * 2015-03-18 2016-09-22 Apceth Gmbh & Co. Kg Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells
JP6890831B2 (ja) 2015-07-08 2021-06-18 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖ予備免疫化および免疫療法
EA201800148A1 (ru) 2015-08-11 2019-01-31 Калиди Биотерапьютикс, Инк. Оспенная вакцина для лечения рака
WO2017036925A1 (en) * 2015-08-28 2017-03-09 Apceth Gmbh & Co. Kg Mesenchymal stem cells for the treatment of metastatic liver disease
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
JP7260898B2 (ja) 2016-01-15 2023-04-19 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド ガンマデルタｔ細胞の活性化のための方法および組成物
JP7153332B2 (ja) 2016-02-08 2022-10-14 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖワクチン接種および免疫療法
EP3426777B1 (en) 2016-03-09 2022-02-16 American Gene Technologies International Inc. Combination vectors and methods for treating cancer
AU2017277499B2 (en) 2016-06-07 2022-07-28 The Pacific Heart, lung & Blood Institute Compositions and methods for treating cancer
EP3468617A4 (en) 2016-06-08 2020-01-22 American Gene Technologies International Inc. INTEGRATED VIRAL ADMINISTRATION SYSTEM AND RELATED METHODS
WO2018009246A1 (en) 2016-07-08 2018-01-11 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
JP7176756B2 (ja) 2016-07-21 2022-11-22 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド パーキンソン病を処置するためのウイルスベクター
KR20190109389A (ko) 2016-11-03 2019-09-25 엑소스템 바이오텍 리미티드 간엽 줄기 세포 집단, 이들의 산물 및 이들의 용도
KR102737836B1 (ko) 2017-04-03 2024-12-03 아메리칸 진 테크놀로지스 인터내셔널 인코포레이티드 페닐케톤뇨증을 치료하기 위한 조성물 및 방법
EP4317422A3 (en) 2017-04-13 2024-05-01 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US11246890B2 (en) 2018-04-03 2022-02-15 The Board Of Trustees Of The Leland Stanford Junior University Systemic targeting of inflammatory sites and enhanced immunomodulatory function by introducing the chimeric antigen receptor (CAR) into mesenchymal stem cells for inflammatory and autoimmune diseases
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
JP2021526865A (ja) * 2018-06-14 2021-10-11 ロマ・リンダ・ユニヴァーシティ 急性骨髄性白血病の処置のための操作された造血幹細胞
SG11202103317XA (en) 2018-10-17 2021-05-28 Senti Biosciences Inc Combinatorial cancer immunotherapy
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
EP3876952A4 (en) 2018-11-05 2022-08-24 American Gene Technologies International Inc. VECTOR SYSTEM FOR EXPRESSING REGULATORY RNA
KR20210091740A (ko) 2018-11-06 2021-07-22 카리디 바이오테라퓨틱스, 인크. 세포-매개된 종양용해 바이러스 요법용 향상된 시스템
US20220241337A1 (en) * 2019-02-22 2022-08-04 The Trustees Of Columbia University In The City Of Newyork Preparing tissues for delivery of therapeutic and diagnostic agents and delivering the agents
SG10201902002SA (en) * 2019-03-06 2020-10-29 Nat Univ Singapore Non-viral modification of mesenchymal stem cells
EP4017512B1 (en) * 2019-08-23 2025-04-02 Orbsen Therapeutics Limited Compositions for monocyte and macrophage polarization and methods of use
JP2023547728A (ja) 2020-11-06 2023-11-13 アーテック メディカル ジーエムビーエイチ 間葉系幹細胞由来の細胞外小胞およびアルファ－１アンチトリプシンを含むウイルス感染症治療用組成物
EP3995130A1 (en) 2020-11-06 2022-05-11 JunctuCell Biomed Manufacturing GmbH A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265564B1 (en) * 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule
US7098185B2 (en) * 1998-05-18 2006-08-29 University College London Polypeptide hormone phosphatonin
US20060057553A1 (en) * 2000-05-30 2006-03-16 Estuardo Aguilar-Cordova Chimeric viral vectors for gene therapy
WO2002069953A1 (en) * 2001-03-01 2002-09-12 The Board Of Regents Of The University Of Texas System Methods of treating lung inflammation
US20030165579A1 (en) * 2002-02-27 2003-09-04 Chih-Hui Lin Euphorbia antiquorum extract, a pharmaceutical composition containing the same and methods for treatment of cancers
EP1544213B1 (en) * 2003-12-19 2008-02-20 Charité - Universitätsmedizin Berlin Use of ligands of the antigen cd52 for the treatment of solid tumours and bone-related cancerous diseases
JP2006194752A (ja) * 2005-01-14 2006-07-27 Sumitomo Metal Mining Co Ltd Ｘ線回折測定における試料固定方法および試料固定具
KR101022401B1 (ko) * 2005-09-29 2011-03-15 아주대학교산학협력단 자살유전자를 발현하는 중간엽 줄기세포를 포함하는 암치료용 조성물
EP2851422A3 (en) 2007-05-24 2015-06-24 Apceth GmbH & Co. KG CD34neg stem cells for the treatment of gastrointestinal disorders

Also Published As

Publication number Publication date
US20120087901A1 (en) 2012-04-12
JP2012523243A (ja) 2012-10-04
EP2419113A1 (en) 2012-02-22
AU2010237130A1 (en) 2011-11-03
JP5727458B2 (ja) 2015-06-03
WO2010119039A1 (en) 2010-10-21
US20170015976A1 (en) 2017-01-19
EP2419113B1 (en) 2017-05-10
IL215581A0 (en) 2011-12-29
CN102695517A (zh) 2012-09-26
KR20120088542A (ko) 2012-08-08
RU2011146048A (ru) 2013-05-20
RU2539099C2 (ru) 2015-01-10
US9434925B2 (en) 2016-09-06
SG175127A1 (en) 2011-11-28
AU2010237130B2 (en) 2015-01-29
CA2758120A1 (en) 2010-10-21
CN102695517B (zh) 2015-01-28
CA2758120C (en) 2014-08-19

Similar Documents

Publication Publication Date Title
BRPI1013771A2 (pt) "células-tronco mesenquimais projetadas e método de uso das mesmas para tratar tumores."
BRPI0909817A2 (pt) uso de células-tronco mesenquimais para tratamento de doenças e distúrbios genéticos
BR112012016203A2 (pt) "métodos para melhoria da proliferaçõ e atividade das células exterminadoras naturais"
BR112014005355A2 (pt) células t de memória central anti-terceiro, métodos de produção e uso das mesmas em transplante e tratamento de doença
SMT201600050B (it) Mezzi e metodi per trattare il dlbcl
BRPI0924921A2 (pt) Métodos de isolar células-tronco mesequimais, de promover proliferação das referidas células e de produção de tecidos diferenciados
MX379016B (es) Composiciones y metodos para tratar enfermedad de gaucher.
CY2017021I1 (el) Υψηλης συναφειας ανθρωπινα αντισωματα προς pcsk9
CL2013000238A1 (es) Uso de inhibores de la succinato deshidrogenasa y/o inhibidores del complejo iii para mejorar la relacion entre microorganismos dañinos y beneficiosos.
BRPI0807132A2 (pt) enzimas para o tratamento de lignocelulósicos, ácidos nucléicos que codificam as mesmas, e metodos e uso das mesmas
BRPI1009871A2 (pt) terapia para promover o crescimento celular
BRPI1009263A2 (pt) alfa-amilases relacionadas com cepa de bacillus megaterium dsm90 e métodos de uso das mesmas.
BR112012009921A2 (pt) métodos para reprogramar células e usos do mesmos
CL2014001299A1 (es) Uso de un conjugado de anticuerpo-fármaco anti-egfrviii (factor de crecimiento epidermico) para tratar tumor.
DK3130923T3 (da) Terapeutiske fremgangsmåder i forbindelse med cancerstamceller
BRPI0921433A2 (pt) uso de anticorpos anti-cs1 para o tratamento de linfomas raros
BRPI1011655A2 (pt) uso de lcat para tratar anemia e disfunção de glóbulos vermelhos
WO2013070881A8 (en) Method for elimination of space through tissue approximation
BRPI1013698A2 (pt) métodos para tratamento com o uso de terapia de combinação
BRPI0912292A2 (pt) composições e métodos para o uso de células no tratamento do tecido cardíaco.
BR112012000882A2 (pt) Preparação cosmética capilar e método para aplicação.
BR112013001089A2 (pt) composição de meio de cultura e método para cultivar células tronco mesenquimais derivadas de âmnio
BRPI1009981A2 (pt) sistemas , métodos e composições para otimizar os enxertos enriquecidos de tecido e célula
AR079889A1 (es) Antagonistas de wnt y metodos de tratamiento y deteccion
BRPI0920891A2 (pt) misturas de alfa-amilase e métodos para uso das referidas misturas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2370 DE 07-06-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.